D. E. Shaw & Co., Inc. Ligand Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 7,151 shares of LGND stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,151

Holding current value

$1.34 Million

% of portfolio

0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$96.67 - $118.22 $691,287 - $845,391	7,151 New	7,151 $812,000
Q2 2024 Aug 14, 2024	SELL	$68.53 - $87.91 $2.53 Million - $3.24 Million	-36,849 Reduced 58.87%	25,743 $2.17 Million
Q1 2024 May 15, 2024	SELL	$68.64 - $89.2 $1.74 Million - $2.26 Million	-25,317 Reduced 28.8%	62,592 $4.58 Million
Q4 2023 Feb 14, 2024	SELL	$49.57 - $72.63 $882,940 - $1.29 Million	-17,812 Reduced 16.85%	87,909 $6.28 Million
Q3 2023 Nov 14, 2023	BUY	$58.86 - $72.67 $3.2 Million - $3.95 Million	54,347 Added 105.79%	105,721 $6.33 Million
Q2 2023 Aug 14, 2023	BUY	$69.53 - $79.33 $141,632 - $161,595	2,037 Added 4.13%	51,374 $3.7 Million
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $128,975 - $151,385	-1,964 Reduced 3.83%	49,337 $3.63 Million
Q4 2022 Feb 14, 2023	BUY	$61.72 - $96.74 $3.17 Million - $4.96 Million	51,301 New	51,301 $3.43 Million
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $2.68 Million - $5.81 Million	-26,913 Reduced 80.84%	6,377 $972,000
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $3.57 Million - $4.7 Million	-44,291 Reduced 57.09%	33,290 $3.31 Million
Q3 2020 Nov 16, 2020	SELL	$89.56 - $126.72 $8.31 Million - $11.8 Million	-92,842 Reduced 54.48%	77,581 $7.4 Million
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $315,248 - $570,892	4,617 Added 2.78%	170,423 $19.1 Million
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $5.65 Million - $9.63 Million	89,236 Added 116.54%	165,806 $12.1 Million
Q4 2019 Feb 14, 2020	BUY	$96.94 - $113.59 $6.28 Million - $7.35 Million	64,744 Added 547.47%	76,570 $7.99 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $666,022 - $927,875	7,722 Added 188.16%	11,826 $1.18 Million
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $1.3 Million - $1.57 Million	-12,101 Reduced 74.67%	4,104 $468,000
Q1 2019 May 15, 2019	SELL	$105.93 - $142.47 $16.2 Million - $21.8 Million	-152,761 Reduced 90.41%	16,205 $2.04 Million
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $17.7 Million - $37.6 Million	138,109 Added 447.58%	168,966 $22.9 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $10.5 Million - $13.6 Million	-49,557 Reduced 61.63%	30,857 $8.47 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $3.76 Million - $5.18 Million	24,909 Added 44.88%	80,414 $16.7 Million
Q1 2018 May 15, 2018	SELL	$138.63 - $182.62 $1.57 Million - $2.07 Million	-11,319 Reduced 16.94%	55,505 $9.17 Million
Q4 2017 Feb 14, 2018	BUY	$128.36 - $147.04 $3.85 Million - $4.41 Million	29,992 Added 81.43%	66,824 $9.15 Million
Q3 2017 Nov 14, 2017	BUY	$120.91 - $137.94 $4.45 Million - $5.08 Million	36,832	36,832 $5.02 Million

Others Institutions Holding LGND

# of Institutions

296

Shares Held

19.6M

Call Options Held

Put Options Held

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $3.15B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account